Shares of Tiziana Life Sciences (TILS) finally started to respond freely to the significant positive drivers on the company, such as being in the run up to the spin out of StemPrintER, into Accustem Sciences, as well as accelerated studies with regard to Foralumab, its first fully human monoclonal antibody. Antibodies have come into focus following the so far successful treatment of President Trump for COVID-19. Tiziana jumped 30p to 204p.
Sticking with the pharma space, and it was the turn of Open Orphan (ORPH) to be a firm market, with the stock up 2p to 23p. This may have been triggered by the run up to a reported international webinar on COVID-19 next week, attended by its hVivo subsidiary.
Multi asset, Africa focused energy company, Kibo Energy (KIBO) was finally getting some keen interest amongst bottom fishers, off the back of the disappearance of a major seller in the market of late. The company was also attracting bullishness on the observation that its stake in Katoro Gold (KAT) is currently worth more than Kibo’s market cap. There may have also been some positive momentum in the run up to a planned investor webinar on October 14.
After years of perhaps underwhelming the stock market, it was the turn of Asiamet Resources (ARS) to offer a pleasant surprise on the upside. This came in the form of the company selling its Indokal subsidiary, part of the BKM Copper project in Indonesia. Investors who largely backed the deal – and with considerable relief, pointed to the way the price achieved at $163m was well above the $124.8m NPV for BKM. Following this event Asiamet will be debt free, have $50m in cash and still have significant assets. Asiamet shares closed up 68% at 4.2p.
There was a second consecutive day of Xtract Resources (XTR) being in the limelight, with an update from the company on its key Manica Hard Rock Project. In it, the company, which recently achieved unsecured and interest free funding of £1m, said that a large part of the initial works had already been completed by Tayanna, a leading open cast mining and construction company.
Alba Mineral Resources (ALBA) has recently been getting investors excited regarding gold in Wales, but the latest from the company was related to its work activities at its 100% owned Thule Black Sands Project in northern Greenland. Alba said that mineral sands specialists IHC Robbins had been appointed to carry out comprehensive metallurgical process development. The shares were up 0.07p to 0.45p.
Fusion Antibody (FAB) was an intriguing market, with talk being that market makers were keeping a tight grip on the shares, leaving them up just 2.5p at 160p. This was despite significant buying in the stock by clued up investors chasing the current a la mode story regarding how important antibodies may be in the pandemic battle. A very tight free float, and a miniscule market cap as compared to a US counterpart, have made some observers of “FAB” wonder why the stock has yet to fully join the 2020 Pharm Boom.
Also up significantly was Osirium (OSI), with a 35% gain. This was achieved off the back of a contract win with a major UK retailer. This should clearly be enough to allow the company to live up to its description of being a leading vendor of cloud based cybersecurity software security. Indeed, given the importance of the deal it was perhaps surprising that the shares were not up more – especially given the way that it recent weeks they have certainly been bubbling up as if something exciting was in the offing.
Disclaimer
Zakmir.com is a purely journalistic website – Zak Mir is a member of the National Union of Journalists. There is no intention here of providing financial advice. It is recommended you seek an independent professional opinion before deciding whether or not to take any action with regard to anything written here.
